Fig. 4.
p53 accumulation after lactacystin treatment in B-CLL but not in normal lymphocytes.
Western blot analyses of β-catenin and nuclear wild-type p53 at different times after lactacystin (2.5 μmol/L) treatment of B-CLL or PBL compared with untreated cells (time 0). Note that an equal amount of protein (derived from 1.5 × 106 cells) was deposited in each lane and visualized by actin protein levels. The results represent analyses of cells from 10 different patients and 10 different normal donors.